Cargando…

Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study

INTRODUCTION: Most studies on intracoronary bone marrow mononuclear cell transplantation for acute myocardial infarction involve treatment 3–7 days after primary percutaneous coronary intervention (PCI); however, the optimal timing is unknown. The present study assessed the therapeutic effect at dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Rongchong, Yao, Kang, Sun, Aijun, Qian, Juying, Ge, Lei, Zhang, Yiqi, Niu, Yuhong, Wang, Keqiang, Zou, Yunzeng, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509778/
https://www.ncbi.nlm.nih.gov/pubmed/26021558
http://dx.doi.org/10.1186/s13287-015-0102-5
_version_ 1782382082381578240
author Huang, Rongchong
Yao, Kang
Sun, Aijun
Qian, Juying
Ge, Lei
Zhang, Yiqi
Niu, Yuhong
Wang, Keqiang
Zou, Yunzeng
Ge, Junbo
author_facet Huang, Rongchong
Yao, Kang
Sun, Aijun
Qian, Juying
Ge, Lei
Zhang, Yiqi
Niu, Yuhong
Wang, Keqiang
Zou, Yunzeng
Ge, Junbo
author_sort Huang, Rongchong
collection PubMed
description INTRODUCTION: Most studies on intracoronary bone marrow mononuclear cell transplantation for acute myocardial infarction involve treatment 3–7 days after primary percutaneous coronary intervention (PCI); however, the optimal timing is unknown. The present study assessed the therapeutic effect at different times after ST-elevation myocardial infarction. METHODS: The present trial was not blinded. A total of 104 patients with a first ST-elevation myocardial infarction and a left ventricular ejection fraction below 50 %, who had PCI of the infarct-related artery, were randomly assigned to receive intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A, n = 27), 3 to 7 days after PCI (group B, n = 26), or 7 to 30 days after PCI (group C, n = 26), or to the control group (n = 25), which received saline infusion performed immediately after emergency PCI. All patients in groups A, B and C received an injection of 15 ml cell suspension containing approximately 4.9 × 10(8) bone marrow mononuclear cells into the infarct-related artery after successful PCI. RESULTS: Compared to control and group C patients, group A and B patients had a significantly higher absolute increase in left ventricular ejection fraction from baseline to 12 months (change: 3.4 ± 5.7 % in control, 7.9 ± 4.9 % in group A, 6.9 ± 3.9 % in group B, 4.7 ± 3.7 % in group C), a greater decrease in left ventricular end-systolic volumes (change: −6.4 ± 15.9 ml in control, −20.5 ± 13.3 ml in group A, −19.6 ± 11.1 ml in group B, −9.4 ± 16.3 ml in group C), and significantly greater myocardial perfusion (change from baseline: −4.7 ± 5.7 % in control, −7.8 ± 4.5 % in group A, −7.5 ± 2.9 % in group B, −5.0 ± 4.0 % in group C). Group A and B patients had similar beneficial effects on cardiac function (p = 0.163) and left ventricular geometry (left ventricular end-distolic volume: p = 0.685; left ventricular end-systolic volume: p = 0.622) assessed by echocardiography, whereas group C showed similar results to those of the control group. Group B showed more expensive care (p < 0.001) and longer hospital stays during the first month after emergency PCI (p < 0.001) than group A, with a similar improvement after repeat cardiac catheterization following emergency PCI. CONCLUSION: Cell therapy in acute myocardial infarction patients that is given within 24 hours is similar to 3–7 days after the primary PCI. TRIAL REGISTRATION: NCT02425358, registered 30 April 2015
format Online
Article
Text
id pubmed-4509778
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45097782015-07-23 Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study Huang, Rongchong Yao, Kang Sun, Aijun Qian, Juying Ge, Lei Zhang, Yiqi Niu, Yuhong Wang, Keqiang Zou, Yunzeng Ge, Junbo Stem Cell Res Ther Research INTRODUCTION: Most studies on intracoronary bone marrow mononuclear cell transplantation for acute myocardial infarction involve treatment 3–7 days after primary percutaneous coronary intervention (PCI); however, the optimal timing is unknown. The present study assessed the therapeutic effect at different times after ST-elevation myocardial infarction. METHODS: The present trial was not blinded. A total of 104 patients with a first ST-elevation myocardial infarction and a left ventricular ejection fraction below 50 %, who had PCI of the infarct-related artery, were randomly assigned to receive intracoronary infusion of bone marrow mononuclear cells within 24 hours (group A, n = 27), 3 to 7 days after PCI (group B, n = 26), or 7 to 30 days after PCI (group C, n = 26), or to the control group (n = 25), which received saline infusion performed immediately after emergency PCI. All patients in groups A, B and C received an injection of 15 ml cell suspension containing approximately 4.9 × 10(8) bone marrow mononuclear cells into the infarct-related artery after successful PCI. RESULTS: Compared to control and group C patients, group A and B patients had a significantly higher absolute increase in left ventricular ejection fraction from baseline to 12 months (change: 3.4 ± 5.7 % in control, 7.9 ± 4.9 % in group A, 6.9 ± 3.9 % in group B, 4.7 ± 3.7 % in group C), a greater decrease in left ventricular end-systolic volumes (change: −6.4 ± 15.9 ml in control, −20.5 ± 13.3 ml in group A, −19.6 ± 11.1 ml in group B, −9.4 ± 16.3 ml in group C), and significantly greater myocardial perfusion (change from baseline: −4.7 ± 5.7 % in control, −7.8 ± 4.5 % in group A, −7.5 ± 2.9 % in group B, −5.0 ± 4.0 % in group C). Group A and B patients had similar beneficial effects on cardiac function (p = 0.163) and left ventricular geometry (left ventricular end-distolic volume: p = 0.685; left ventricular end-systolic volume: p = 0.622) assessed by echocardiography, whereas group C showed similar results to those of the control group. Group B showed more expensive care (p < 0.001) and longer hospital stays during the first month after emergency PCI (p < 0.001) than group A, with a similar improvement after repeat cardiac catheterization following emergency PCI. CONCLUSION: Cell therapy in acute myocardial infarction patients that is given within 24 hours is similar to 3–7 days after the primary PCI. TRIAL REGISTRATION: NCT02425358, registered 30 April 2015 BioMed Central 2015-05-29 /pmc/articles/PMC4509778/ /pubmed/26021558 http://dx.doi.org/10.1186/s13287-015-0102-5 Text en © Huang et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Huang, Rongchong
Yao, Kang
Sun, Aijun
Qian, Juying
Ge, Lei
Zhang, Yiqi
Niu, Yuhong
Wang, Keqiang
Zou, Yunzeng
Ge, Junbo
Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title_full Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title_fullStr Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title_full_unstemmed Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title_short Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study
title_sort timing for intracoronary administration of bone marrow mononuclear cells after acute st-elevation myocardial infarction: a pilot study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509778/
https://www.ncbi.nlm.nih.gov/pubmed/26021558
http://dx.doi.org/10.1186/s13287-015-0102-5
work_keys_str_mv AT huangrongchong timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT yaokang timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT sunaijun timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT qianjuying timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT gelei timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT zhangyiqi timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT niuyuhong timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT wangkeqiang timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT zouyunzeng timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy
AT gejunbo timingforintracoronaryadministrationofbonemarrowmononuclearcellsafteracutestelevationmyocardialinfarctionapilotstudy